Well-defined, large sample of DLB patients with a clinical diagnosis of DLB supported by DATRetrospective design – not all features reported for all patientsCSF total alpha-synuclein is not yet validated as a clinically useful marker in DLB – there may be differences in sensitivity between different alpha-synuclein speciesA small number of patients had normal DAT imaging, which is not supportive of DLB diagnosis, but clinical diagnosis made in tertiary centers. The gene discussed is SLC6A3; the disease is Lewy body dementia.